Review Article

Osteocalcin Serum Levels in Gestational Diabetes Mellitus and Their Intrinsic and Extrinsic Determinants: Systematic Review and Meta-Analysis

Raigam J. Martinez-Portilla,1,2 Jose R. Villafan-Bernal,3,4,5 Diana L. Lip-Sosa,1 Eva Meler,1 Jordi Clotet,1 Francisco J. Serna-Vela,5 Sergio Velazquez-Garcia,6 Leopoldo C. Serrano-Diaz,7 and Francesc Figueras1,8

1Fetal i+D Fetal Medicine Research Center, BCNatal-Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), IDIBAPS, University of Barcelona, Spain
2Maternal-Fetal Medicine and Therapy Research Center Mexico in behalf of the Iberoamerican Research Network in Translational, Molecular and Maternal-Fetal Medicine, Mexico
3Mexican Consortium of Biomedicine, Biotechnology and Health Dissemination-Consortium BIO2-DIS, Mexico
4CONACYT Researcher at the Department of Surgery, Health Science Center, Autonomous University of Aguascalientes, Mexico
5Center for Health Sciences, Autonomous University of Aguascalientes, Mexico
6CIMeTA Research Unit-ISSEA, Mexico
7Women’s Hospital of the State of Aguascalientes-ISSEA, Mexico
8Center for Biomedical Research on Rare Diseases (CIBER-ER), Madrid, Spain

Correspondence should be addressed to Francesc Figueras; ffiguera@clinic.ub.es

Received 24 July 2018; Revised 11 October 2018; Accepted 29 October 2018; Published 30 December 2018

Academic Editor: Michaelangela Barbieri

Copyright © 2018 Raigam J. Martinez-Portilla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Undercarboxylated osteocalcin (ucOC) increases insulin release and insulin resistance in mice. In humans, evidence is scarce but a correlation of ucOC and total osteocalcin (tOC) with glycemic status markers has been demonstrated. The relationship of ucOC and tOC with gestational diabetes mellitus (GDM) has been even less characterized. Objective. To assess the mean difference of tOC and ucOC serum concentrations among nondiabetic pregnant women and women diagnosed as GDM in the second trimester of pregnancy and to determine the possible intrinsic and extrinsic contributors to this difference. Methods. A systematic search was performed to identify relevant studies published in English and Spanish using PubMed, SCOPUS, ISI Web of Knowledge, and PROSPERO database for meta-analysis. Observational studies measuring mean serum levels of osteocalcin among GDM, with at least 10 subjects analyzed in each group were selected. Mean difference (MD) by random effects model was used. Heterogeneity between studies was assessed using Cochran’s Q, H, and I² statistics. Results. From 38 selected studies, 5 were retained for analysis for a total of 1119 pregnant women. Serum concentrations of tOC were not significantly different among women with GDM and nondiabetic pregnant controls (MD: 1.56; 95% CI: −0.70 to 3.82; p = 0.175). Meanwhile, ucOC serum levels were significantly higher among women with GDM (MD: 1.17; 95% CI: 0.24 to 2.11; p = 0.013). The only factor influencing tOC was the UV index, showing a reduction in mean difference between GDM and controls when exposed to higher concentrations of UV rays. Conclusions. This meta-analysis provides evidence to support the use of ucOC as a potential marker for GDM rather than tOC, yielding very little variability among studies and no difference among methods or brands used for its analysis.
1. Introduction

Gestational diabetes mellitus (GDM) is defined as any glucose impairment with first onset or recognition during pregnancy [1]. With a prevalence within 2 to 6%, which is increasing worldwide, this condition represents a leading cause of adverse perinatal outcomes [2], with delayed effects both for women and children [3, 4]. Diagnosis of GDM usually happens in an advanced gestational age, limiting preventive strategies. Development of prediction models for GDM is a challenge to contemporary fetal-maternal medicine.

Osteocalcin (OC) is a bone-derived protein that takes part in bone metabolism [5]. About 10% to 30% of osteocalcin is released into the main circulation, which is later cleared by the liver and kidney [6–8]. The three primary forms of OC are carboxylated (cOC), undercarboxylated (ucOC), and total osteocalcin (tOC) [9]; these three biochemical markers can be separately measured in blood by different methods such as RIA (radioimmunoassay), IRMA (immunoradiometric assay), ELISA (enzyme-linked immunoassay), or electrochemiluminescence immunoassay (ECLIA).

From a clinical point of view, tOC and ucOC serum levels are lower among patients with type 1 and type 2 diabetes [10–27], while only a few studies have assessed the mean concentration of cOC suggesting increased levels in individuals with type 2 diabetes [26]. Some studies have shown that ucOC increases insulin secretion and proliferation of pancreatic beta-cells. It also increases adiponectin secretion from adipose tissue, reducing fat mass and increasing energy expenditure by increasing the expression of genes involved in beta-oxidation [28]. Nonetheless, gestational diabetes mellitus (GDM) is a different entity defined as glucose intolerance resulting in hyperglycemia of variable severity with onset or first recognition during pregnancy [1]. Maternal physiological changes during pregnancy lead to a decrease in fasting glucose at early pregnancy and continuously during gestation, together with a marked decline in insulin sensitivity during second and third trimester [29, 30]. One study performed in pregnant women demonstrated that tOC serum levels are higher during the first trimester of pregnancy in women subsequently developing GDM when compared to controls [31]. However, studies measuring tOC and ucOC during second trimester in nonprevious diabetic women have yielded controversial results [32, 33].

Defining the changes in serum levels of proteins or hormones related to insulin resistance or glucose tolerance such as tOC and ucOC among women developing GDM is vital for adequate future prediction models aimed to determine which women are at risk for developing this disease [34]. Indeed, a model combining maternal characteristics plus insulin-resistance-related proteins could lead to effective predictive algorithms for GDM [35].

The aim of this systematic review and meta-analysis is to quantify the changes of tOC and ucOC serum concentrations in women diagnosed with GDM in the second trimester of pregnancy and to determine the possible intrinsic and extrinsic determinants of these changes.

2. Methods

2.1. Protocol Registration. Before data extraction, the project was registered in the PROSPERO international prospective register of systematic reviews (registration number: CRD42018091727).

2.2. Eligibility Criteria, Information Sources, and Search Strategy. A systematic search was performed using PubMed, EBSCO, ISI Web of Science, and PROSPERO database for meta-analysis to identify relevant studies published in English or Spanish, without publication time restrictions. Institutional review board approval is not required for systematic reviews in our institution. References of relevant publications were manually searched for additional potentially relevant studies. The first search was run on May 20, 2017. Afterward, an update was extended until March 23, 2018.

This review was carried out adhering to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [36] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews and meta-analysis [37, 38]. Two independent evaluators (R.M. and R.V.) assessed abstracts identified as relevant, both blinded to authorship, authors’ institutional affiliation, and study results. If the abstract fulfilled inclusion criteria, full-text articles were then reviewed. A third investigator (F.F.) independently settled any disagreement between evaluators. In case of relevant studies with missing information, corresponding authors were reached by e-mail to request such data. Annex 1 of supplemental material details the search strategy and query syntaxes.

2.3. Study Selection. The inclusion criteria for this systematic review were observational studies (prospective or retrospective) on women diagnosed with GDM between 24 and 28 weeks of gestation and their respective nondiabetic pregnant controls, with at least ten women in each group and reporting serum levels of OC.

2.4. Data Extraction. The following information was extracted on a datasheet based on Cochrane Consumers and Communication Review Group’s data extraction template [39]: author, year of publication, country where the study was conducted, study period, type of study, original inclusion and exclusion criteria, total number of patients included in the study, number of participants with GDM, number of nondiabetic pregnant women, osteocalcin quantification method, form of osteocalcin determined, mean maternal age at analysis, mean maternal body mass index (BMI), mean gestational age at measurement of OC, method of quantification, brand of the kit used for the measurement, and mean UV index as a surrogate of sun exposure.

2.5. Assessment of Risk of Bias. Two reviewers (R.M. and D.L.) independently assessed the quality of the selected studies. Quality assessment of observational studies was carried out using the Newcastle-Ottawa scale for case-control studies and cohort studies. Each study was judged on three dimensions: the selection of the study groups, the
comparability of the groups, and the ascertainment of the exposure. One star was given for each signaling question among each dimension. For a total of 9 possible stars, studies with 7 or more stars were considered as high quality [40].

2.6. Data Analysis. Extracted results were pooled in the meta-analysis. Data analysis was performed as recommended by the Cochrane handbook in the following manner: tOC and uOC concentrations within the comparison of GDM and nondiabetic pregnant controls. The effect size was expressed as mean difference (MD) by random effects models (REM) weighting by the inverse of the variance since all studies used randomly sampled [41].

Results are presented using forest plots including the MDs for the main groups (cases and controls). For subgroup analysis, a mixed effects model (MEM) was employed [42].

Between-study variability was assessed using the \( I^2 \) and Cochran’s Q and \( I^2 \) statistics [43]. The contribution of individual-study heterogeneity was visually assessed by Baujat plots [44].

Multiple metaregressions were performed to add another approach for unexplained heterogeneity and to determine which variables influenced tOC and uOC serum levels. When enough information was available, we used the following covariates: mean gestational age at inclusion; mean gestational age at diagnosis of GDM was 26.6 (SD 1.5) weeks; this was also influenced by the higher mean UV index. Mean UV index was the only variable significantly influencing serum levels of OC; the higher the UV index, the lower the mean difference between women with GDM and nondiabetic pregnant controls (2.28; 95% CI: –0.43 to 5.00; \( p = 0.099 \)). A Q value of 4.42 with 2 degrees of freedom and \( p < 0.01 \) provides evidence that the effect size varies across studies. \( I^2 \) indicates that 88% of the variation can be attributed to true effect rather than random error (Figure 2).

Baujat plot showed that the study from Hossein-nezhad et al. [32] contributed the most to the overall heterogeneity and influenced the most to the overall results (Figure 3).

Contour-enhanced funnel plot showed no significant publication bias (Figure 4), also quantified by Egger method (estimate: –0.670; \( p = 0.119 \)).

According to the cumulative analysis, there was no trend towards more significant results in smaller studies, reducing the probability of publication bias (Figure 5).

3. Results

3.1. Study Selection and Study Characteristics. A total of 38 studies were identified by database searching, with one additional study included manually. Of them, eight studies were eligible for full-text review. After review, five studies [32, 33, 48–50] were retained for the systematic review and meta-analysis. Figure 1 depicts the review flow diagram.

Reasons for excluding three full-text studies were as follows: one of them used the same cohort of another included study in our analysis [51], while the second one performed the diagnostic tests for GDM from 24 to 32 weeks of gestation [52]. The last excluded study was due to inclusion of women with a diagnosis of diabetes before pregnancy [53]. The following authors were reached by mail and they provided aggregated data on their published studies: Tabatabaei et al. [49], Saucedo et al. [33], and Srichomkwun et al. [50]. Annex 2 in the supplemental material details the shared information. Also, the characteristics of the included articles are described in Table 1.

We used the Newcastle-Ottawa scale for study-quality assessment in observational studies. From a total of 9 possible rating points, three studies [32, 48, 50] presented 6 points mainly due to lack of representativeness of the cases, lack of nonresponse rate description, or no description for control selection. Two studies [33, 49] had 7 points or more due to the representativeness of the cases, study controls for each additional outcome, or lack of nonresponse rate description. Tables 2 and 3 show the full Newcastle-Ottawa scale assessment. From the five included studies [32, 33, 48–50], a total of 1119 pregnant women underwent assessment for OC serum concentrations; from these, 23% (259/1119) were diagnosed as GDM. The mean reported maternal age among studies was 30.5 (SD 2.3) years. Also, the mean BMI was 27.3 (SD 3) kg/m² with a weight gain of 11.7 (SD 3.7) kg. Mean gestational age at diagnosis of GDM was 26.6 (SD 1.5) weeks; this was also the gestational age at enrollment and measurement of OC.

3.2. Total Osteocalcin among Gestational Diabetes Mellitus. Three studies [32, 33, 50] had information regarding tOC concentrations among GDM. There was no statistically significant mean difference between women with GDM and nondiabetic pregnant controls (2.28; 95% CI: –0.43 to 5.00; \( p = 0.099 \)). A Q value of 4.42 with 2 degrees of freedom and \( p < 0.01 \) provides evidence that the effect size varies across studies. \( I^2 \) indicates that 88% of the variation can be attributed to true effect rather than random error (Figure 2).

Baujat plot showed that the study from Hossein-nezhad et al. [32] contributed the most to the overall heterogeneity and influenced the most to the overall results (Figure 3).

Contour-enhanced funnel plot showed no significant publication bias (Figure 4), also quantified by Egger method (estimate: –0.670; \( p = 0.119 \)).

According to the cumulative analysis, there was no trend towards more significant results in smaller studies, reducing the probability of publication bias (Figure 5).

3.3. Subgroup Analysis for tOC. Formal assessment of heterogeneity could not be performed by subgroup analysis since all studies differed among solar exposition, brand, and method for OC measurement.

3.4. Metaregressions for tOC. Several covariates were used to assess their influence on the mean serum concentrations of OC. Mean UV index was the only variable significantly influencing serum levels of OC; the higher the UV index, the lower the mean difference of tOC between women with GDM and pregnant controls (estimate: –0.812; 95% CI: –1.22 to –0.39; \( p < 0.001 \)). The effect of UV index accounted for 100% of the heterogeneity in this sample (\( R^2 = 1.0 \)), leaving no residual heterogeneity (\( I^2 = 0 \% \)). Figure 6 shows the metaregression for mean UV index.
3.5. Undercarboxylated Osteocalcin among Gestational Diabetes Mellitus. Four studies [33, 48–50] had information regarding ucOC concentrations among GDM. Mean serum levels of ucOC were significantly higher in women with GDM when compared to nondiabetic pregnant women (1.17; 95% CI: 0.24 to 2.11; \(p = 0.013\)). Q value of 2.64 with 3 degrees of freedom and \(p = 0.45\) provides evidence that the true-effect size does not significantly vary across studies. \(I^2\) also depicts this true-effect variability to be 0% (Figure 7).

Prediction interval from −0.88 to 3.22 shows the probability of a future ucOC measurements to lie within this range. Baujat plot showed that the study from Winhofer et al. [48] contributed the most to the overall heterogeneity among studies, while the study from Srichomkwu et al. [50] influenced the most to the overall results (Figure 8).

Contour-enhanced funnel plot showed no significant publication bias (Figure 9), also quantified by Egger method (estimate: −0.670; \(p = 0.119\)).

According to the cumulative analysis, there was a trend towards more significant results in smaller studies, increasing the probability of publication bias (Figure 10).

3.6. Subgroup Analysis for ucOC. Formal assessment of heterogeneity showed that the use of ELISA as the method for ucOC analysis depicted similar results between studies. No added variability was found in this subgroup (\(I^2 = 0\%\)). Figure 11 shows the forest plot for method analysis. Also, no covariate significantly influenced the pooled mean difference for ucOC.

4. Discussion

4.1. Main Findings. There are some crucial points elucidated by the present study. (1) There is no significant difference in tOC concentrations among women with GDM and nondiabetic pregnant controls during the second trimester (at time of GDM screening). (2) Serum concentrations of ucOC are significantly higher in women with GDM when compared to nondiabetic controls. (3) The only extrinsic factor influencing the serum concentrations of tOC is the UV index, showing an inverse correlation between the mean difference in tOC and the level of exposition to UV rays. (4) There was no intrinsic factor such as maternal age, BMI, fasting
| Study                | Year | Country   | Type of study | Inclusion criteria                                                                 | Exclusion criteria                                                                 | Diagnostic criteria for GDM | Type of osteocalcin | Analysis method | Study participants | Number of nondiabetic women | Number of diabetic women |
|---------------------|------|-----------|---------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------|---------------------|------------------|----------------------|--------------------------|--------------------------|
| Winhofer 2010 Iran | Case control | Healthy pregnant women, who were referred from the department of obstetrics and gynecology to the outpatient clinic for routine glucose tolerance testing between the 24th and 28th gestational weeks | History of GDM or obstetric complications in a previous pregnancy, any history of impaired glucose tolerance, or signs of fetal macrosomia. Previous OGTT during pregnancy | One-step: 75 g of glucose (5.5, 10.0, and 7.8 mmol/l cutoff at 0, 1, and 2h) | ucOC | ELISA for tOC | 78                | 52                    | 26                      |
| Hosseinnejhad 2010 Iran | Case control | Pregnant women without previous history of diabetes mellitus who referred to the clinics for prenatal care during the first half of the pregnancy | None | Two-step: 50 g if >7.2 mmol/L, 100 g | tOC | ELISA | 695                | 644                   | 51                      |
| Tabatabaei 2014 Canada | Cohort | Healthy pregnant Caucasian women and women with GDM having singleton and term pregnancies with gestation duration of 37 to 42 weeks. With high risk of GDM (obesity and previous history of GDM) | History or new diagnosis of corticosteroid-treated asthma, liver disease, renal disease, Crohn's disease, ulcerative colitis, celiac disease, medication known to affect bone metabolism, and history of type 1 diabetes or type 2 diabetes | Two-step: 50 g if >7.2 mmol/L, 100 g | ucOC | ELISA | 96                | 48                    | 48                      |
| Saucedo 2015 Mexico | Case control | Nongestational diabetic women and gestational diabetic women screened at 24–28 weeks | History of arterial hypertension, renal disease, liver disease, thyroid disorders, and other endocrine or chronic diseases | Two-step: 50 g if >7.2 mmol/L, 100 g | tOC & ucOC | IRA for tOC & ELISA for ucOC | 120               | 60                    | 60                      |
| Srichomkwun 2015 Thailand | Case control | Pregnant women without risk of gestational diabetes mellitus | History of DM before pregnancy, twin or multiple pregnancy, or significant medical problem, such as cardiovascular, liver, or renal disease | Two-step: 50 g if >7.2 mmol/L, 100 g (cutoff Carpenter Coustan 5.3, 10.0, 9.2, and 8.1 mmol/L at 0, 1, 2, and 3 h) | tOC & ucOC | ELISA | 130               | 56                    | 74                      |

tOC: total osteocalcin; ucOC: undercarboxylated osteocalcin; ELISA: electrochemiluminescence immunoassay; IRA: immunoradiometric assay; GDM: gestational diabetes mellitus.
Table 2: Newcastle-Ottawa scale for case-control studies.

| Study             | Author   | Year | Is the case definition adequate? | Selection Representativeness of the cases | Selection of controls | Definition of controls | Study controls for main outcome | Study controls for additional outcomes | Ascertainment of exposure | Exposure Same method of ascertainment for cases and controls | Nonresponse rate | Stars |
|-------------------|----------|------|----------------------------------|------------------------------------------|-----------------------|-----------------------|---------------------------------|-----------------------------------|-------------------------|-------------------------------------------------------------|------------------|-------|
| Winhofer          | 2010     | *    | *                                | *                                        | *                     | *                     | *                               | *                                 | *                       | *                                                           |      6            |       |
| Suceso            | 2015     | *    |                                  | *                                        | *                     | *                     | *                               | *                                 | *                       | *                                                           |      7            |       |
| Tabatabaei        | 2014     | *    |                                  | *                                        | *                     | *                     | *                               | *                                 | *                       | *                                                           |      7            |       |
| Srichomkwun       | 2015     | *    |                                  | *                                        |                       |                       | *                               | *                                 | *                       | *                                                           |      6            |       |
| Study                        | Author           | Year | Representativeness of the exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Study controls for main outcome | Study controls for additional outcomes | Ascertainment of outcome | Exposure Was follow-up enough for outcomes to occur | Adequacy of follow-up cohorts | Stars |
|------------------------------|------------------|------|-----------------------------------------|-----------------------------------|---------------------------|------------------------------------------------------------------------|--------------------------------|---------------------------------------|--------------------------|------------------------------------------------------|-------------------------------|-------|
| Hossein-nezhad              | 2010             | *    | *                                       | *                                 | *                         | *                                                                      | *                              | *                                     | *                        | *                                                     |                               | 6     |
insulin, fasting glucose, triglycerides, or gain weight during pregnancy, significantly influencing the mean difference of ucOC or tOC. Finally, (5) ELISA as a method for measuring ucOC was the only one comparable among studies, showing no heterogeneity and yielding similar results.

The molecular mechanisms underlying OC differences among pregnant and nonpregnant women have not been yet described. One of the reasons why OC may be higher among women with GDM is the fact that placental-induced insulin resistance reaches its peak between 24 and 28 weeks of gestation. This insulin resistance leads to an increase in insulin secretion by pancreatic B-cells as a compensatory mechanism that derives in an increased anabolic feature on bone metabolism via IGF-1, therefore, influencing OC concentrations especially during the second trimester of pregnancy as described by Winhofer et al. [48].

Similar to our results, the study of Telejko et al. [52] showed no significant difference in tOC levels among women with and without GDM. This study was excluded due to the inclusion of women after 28 weeks of gestation as defined previously. The study conducted by Martinez et al. [53] showed an increase of tOC concentrations among women with diabetes, which was also discarded from our meta-analysis due to the inclusion of prediabetic patients.

4.2. Clinical Implications. Because GDM is usually diagnosed late in pregnancy, early preventive strategies are precluded. Indeed, there is good evidence that timely diagnosis and treatment of GDM by dietary advice, blood glucose monitoring, and insulin therapy when needed significantly reduce perinatal complications such as preeclampsia or macrosomia [54, 55]. Furthermore, there is mounting evidence that
lifestyle interventions early in pregnancy in high-risk women reduce the risk of developing GDM and its associated complications [56, 57]. Thus, developing predictive models for GDM is a challenge in contemporary fetal-maternal medicine. However, the models described so far have limited predictive capacity. At least five predictive models are aiming
to assess the predictive performance for GDM during the first trimester based on maternal characteristics, but none of them have found more than 55% prediction based on these variables. Also, their described AUC ranged from 0.703 to 0.832 [58–62], showing modest overall results. Our study suggests that OC levels may have the potential to improve current predictive strategies based on previous maternal characteristic models.

4.3. Strengths and Limitations. There are two main strengths of our study: firstly, we conducted a rigorous systematic review by independent reviewers and a third one for evaluation, assessment of bias, and database searching was also done by independent investigators all blinded to authorship and hospital where the study was conducted, allowing us to minimize bias when selecting publications for inclusion. Finally, an exhaustive analysis for assessment of intrinsic and extrinsic factors was performed to determine the influence that each one had on the mean difference between GDM and controls.

The main limitation of this study is the small number of publications found in the literature. This limitation is not due to the search strategy but to the real limited number of published papers aiming to measure OC in GDM. Also, there are other causes that may influence OC concentration among women with gestational diabetes such as thyroid diseases or smoking status, but due to the limited information of all possible causes described in each study, it was implausible for us to analyze other causes on individual basis.

4.4. Osteocalcin as a Predictive Protein for Gestational Diabetes Mellitus. As mentioned before, OC is implicated
Contribution to overall heterogeneity

Influence on overall result

Srichomkwun 2014
Saucedo 2015
Tabatabaei 2014
Winhofer 2010

Figure 8: Baujat plot for the mean difference and contribution to heterogeneity among studies measuring ucOC.

Figure 9: Funnel plot for publication bias assessment among studies measuring ucOC.
not only in bone metabolism but in the function of the whole body by exerting its effect when binding to the GPRC6A receptor [28, 63, 64]. The potential role for OC as a predictive protein for GDM comes from previous studies relating knockout mice for GPRC6A (OC receptor) and later smaller pancreatic islet size, lower insulin content, lower pancreatic weight, lower number of islets, lower insulin mRNA expression, and lower insulin secretion in response to osteocalcin with glucose intolerance [65]. Also, the study of Papastefanou and colleagues [31] reported that an elevation of tOC serum levels in maternal serum during the first trimester of gestation is a significant predictor for GDM as a standalone parameter (AUC 0.61) or in combination with maternal and pregnancy characteristics (AUC 0.80). Our study adds to the current knowledge by showing that ucOC is the type of OC that has more pronounced changes in

\[ \text{Mean difference} \]

\[ 0.69 (0.24, 1.17) \]

\[ 0.81 (0.24, 1.85) \]

\[ 0.92 (0.07, 1.92) \]

\[ 1.17 (0.24, 2.11) \]

**Figure 10**: Cumulative forest plot among studies measuring ucOC.

**Figure 11**: Forest plot for subgroup analysis on the methods used for measuring ucOC.
women with GDM. The next research step would be to assess if first-trimester ucOC adds to other existing algorithms in predicting GDM [35].

5. Conclusions and Implications

This meta-analysis provides evidence to support the use of ucOC as a potential marker for GDM rather than tOC, probably because the latter is more influenced by baseline UV exposure. In addition, our study also suggests that measuring ucOC during pregnancy also has the advantage of reduced variability, regardless of the platforms or methods used.

Additional Points

Condensation. This meta-analysis provides evidence to support the use of ucOC as a potential marker for GDM rather than tOC, yielding very little variability among studies and no difference among methods or brands used for its analysis.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

Raigam J. Martinez-Portilla and Jose R. Villafan-Bernal are co-first authors.

Acknowledgments

We would like to acknowledge Dr. Hope Wiler, Dr. Renata Saucedo García, and Dr. Weerapan Khovidhunkit for sharing their original databases. Your willingness to contribute to our study enhances the world of research.

Supplementary Materials

Supplementary 1. Annex 1: query syntax for data search. Supplementary 2. Annex 2: shared information from other authors.

References

[1] B. E. Metzger, D. R. Coustan, and Organizing Committee, “Summary and recommendations of the fourth international workshop-conference on gestational diabetes mellitus,” Diabetes Care, vol. 21, pp. B161–B167, 1998.
[2] J. Djelmis, M. Pavic, V. Mulliqi Kotori, I. Pavlic Renar, M. Ivanisevic, and S. Oreskovic, “Prevalence of gestational diabetes mellitus according to IADPSG and NICE criteria,” International Journal of Gynecology & Obstetrics, vol. 135, no. 3, pp. 250–254, 2016.
[3] D. Farrar, M. Simmonds, M. Bryant et al., “Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and meta-analysis,” BMJ, vol. 354, article i694, 2016.
[4] S. Burlina, M. G. Dalfrà, and A. Lapolla, “Short- and long-term consequences for offspring exposed to maternal diabetes: a review,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 32, no. 4, pp. 687–694, 2017.
[5] P. V. Hauschka, J. B. Lian, D. E. Cole, and C. M. Gundberg, “Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone,” Physiological Reviews, vol. 69, no. 3, pp. 990–1047, 1989.
[6] M. J. Seibel, “Biochemical markers of bone turnover part I: biochemistry and variability,” Clinical Biochemist Reviews, vol. 26, no. 4, pp. 97–122, 2005.
[7] P. D. Delmas, D. M. Wilson, K. G. Mann, and B. L. Riggs, “Effect of renal function on plasma levels of bone Gla-protein,” The Journal of Clinical Endocrinology & Metabolism, vol. 57, no. 5, pp. 1028–1030, 1983.
[8] W. Farrugia and R. A. Melick, “Metabolism of osteocalcin,” Calcified Tissue International, vol. 39, no. 4, pp. 234–238, 1986.
[9] J. R. Villafán-Bernal, S. Sánchez-Enríquez, and M. V. J. Francisco, “Molecular modulation of osteocalcin and its relevance in diabetes (review),” International Journal of Molecular Medicine, vol. 28, no. 3, pp. 283–293, 2011.
[10] Z. Berberoglu, A. Gursoy, N. Bayraktar, A. C. Yazici, N. Bascil Tutuncu, and N. Guvener Demirag, “Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 9, pp. 3523–3530, 2007.
[11] A. B. Choudhury, P. D. Sarkar, D. K. Sakalley, and S. B. Petkar, “Role of adiponectin in mediating the association of osteocalcin with insulin resistance and type 2 diabetes: a cross sectional study in pre- and post-menopausal women,” Archives of Physiology and Biochemistry, vol. 120, no. 2, pp. 73–79, 2014.
[12] D. M. S. L. Cutrim, F. A. Pereira, F. J. A. Paula, and M. C. Foss, “Lack of relationship between glycemic control and bone mineral density in type 2 diabetes mellitus,” Brazilian Journal of Medical and Biological Research, vol. 40, no. 2, pp. 221–227, 2007.
[13] K. K. Danielson, M. E. Elliott, T. LeCaire, N. Binkley, and M. Palta, “Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes,” Osteoporosis International, vol. 20, no. 6, pp. 923–933, 2009.
[14] D. Gogas Yavuz, L. Keskin, S. Kyucu et al., “Vitamin D receptor gene BsmI, FokI, ApaI, TaqI polymorphisms and bone mineral density in a group of Turkish type 1 diabetic patients,” Acta Diabetologica, vol. 48, no. 4, pp. 329–336, 2011.
[15] R. M. Hussein, “Biochemical relationships between bone turnover markers and blood glucose in patients with type 2 diabetes mellitus,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 11, pp. S369–S372, 2017.
[16] E. Y. Liu, J. Wactawski-Wende, R. P. Donahue, J. Dmochowski, K. M. Hovey, and T. Quattrin, “Does low bone mineral density start in post-teenage years in women with type 1 diabetes?,” Diabetes Care, vol. 26, no. 8, pp. 2365–2369, 2003.
[17] L. D. Mastrandrea, J. Wactawski-Wende, R. P. Donahue, K. M. Hovey, A. Clark, and T. Quattrin, “Young women with type 1 diabetes have lower bone mineral density that persists over time,” Diabetes Care, vol. 31, no. 9, pp. 1729–1735, 2008.
[18] T. Neumann, S. Lodes, B. Kästner et al., “Osteocalcin, adipokines and their associations with glucose metabolism in type 1 diabetes,” Bone, vol. 82, pp. 50–55, 2016.
[19] J. M. Olmos, J. L. Pérez-Castrillón, M. T. García, J. C. Garrido, J. A. Amado, and J. González-Macías, “Bone densitometry and biochemical bone remodeling markers in type 1 diabetes mellitus,” Bone and Mineral, vol. 26, no. 1, pp. 1–8, 1994.
[20] S. Sanchez-Enríquez, I. T. Ballesteros-Gonzalez, J. R. Villafán-Bernal et al., “Serum levels of undercarboxylated osteocalcin
are related to cardiovascular risk factors in patients with type 2 diabetes mellitus and healthy subjects,” World Journal of Diabetes, vol. 8, no. 1, pp. 11–17, 2017.

[21] P. D. Sarkar and A. B. Choudhury, “Relationship of serum osteocalcin levels with blood glucose, insulin resistance and lipid profile in central Indian men with type 2 diabetes,” Archives of Physiology and Biochemistry, vol. 118, no. 5, pp. 260–264, 2012.

[22] P. D. Sarkar and A. B. Choudhury, “Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 12, pp. 1631–1635, 2013.

[23] K. Suzuki, T. Kurose, M. Takizawa et al., “Osteocalcin is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density,” Diabetes Research and Clinical Practice, vol. 68, no. 2, pp. 117–125, 2005.

[24] M. Takizawa, K. Suzuki, T. Matsubayashi et al., “Increased bone resorption may play a crucial role in the occurrence of osteopenia in patients with type 2 diabetes: possible involvement of accelerated ppolay pathway in its pathogenesis,” Diabetes Research and Clinical Practice, vol. 82, no. 1, pp. 119–126, 2008.

[25] A. Perrotti, F. Basciani, F. Carle, G. Morgese, and F. Chiarelli, “Calcium metabolism in adolescents and young adults with type 1 diabetes mellitus without and with persistent microalbuminuria,” Journal of Endocrinological Investigation, vol. 22, no. 3, pp. 198–202, 1999.

[26] J. R. Villafáñ-Bernal, M. A. Llamas-Covarrubias, J. F. Muñoz-Valle et al., “A cut-point value of uncarboxylated to carboxylated index is associated with glycemic status markers in type 2 diabetes,” Journal of Investigative Medicine, vol. 62, no. 1, pp. 33–36, 2014.

[27] B. B. Yeap, H. Alfonso, S. A. P. Chubb et al., “Higher serum uncarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 1, pp. 63–71, 2015.

[28] N. K. Lee, H. Sowa, E. Hinoi et al., “Endocrine regulation of energy metabolism by the skeleton,” Cell, vol. 130, no. 3, pp. 456–469, 2007.

[29] P. M. Catalano, E. D. Tzybir, N. M. Roman, S. B. Amini, and E. A. H. Sims, “Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women,” American Journal of Obstetrics & Gynecology, vol. 165, no. 6, pp. 1667–1672, 1991.

[30] J. L. Mills, L. Jovanovic, R. Knopp et al., “Physiological reduction in fasting plasma glucose concentration in the first trimester of normal pregnancy: the diabetes in early pregnancy study,” Metabolism, vol. 47, no. 9, pp. 1140–1144, 1998.

[31] I. Papastefanou, M. Eleftheriades, D. Kappou et al., “Maternal serum osteocalcin at 11-14 weeks of gestation in gestational diabetes mellitus,” European Journal of Clinical Investigation, vol. 45, no. 10, pp. 1025–1031, 2015.

[32] A. Hosseinzadeh, Z. Maghbbooli, K. Mirzaei, M. Rahmani, and B. Larjani, “Osteocalcin and cross-laps status among women with gestational diabetes mellitus during pregnancy,” Journal of Diabetes and Metabolic Disorders, vol. 9, pp. 1–7, 2010.

[33] R. Saucedo, G. Rico, G. Vega et al., “Osteocalcin, under-carboxylated osteocalcin and osteopontin are not associated with gestational diabetes mellitus but are inversely associated with leptin in non-diabetic women,” Journal of Endocrinological Investigation, vol. 38, no. 5, pp. 519–526, 2015.

[34] A. M. Maged, G. A. F. Moety, W. A. Mostafa, and D. A. Hamed, “Comparative study between different biomarkers for early prediction of gestational diabetes mellitus,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 27, no. 11, pp. 1108–1112, 2014.

[35] C. E. Powe, “Early pregnancy biochemical predictors of gestational diabetes mellitus,” Current Diabetes Reports, vol. 17, no. 2, p. 12, 2017.

[36] D. F. Group, J. A. Berlin, S. C. Morton et al., “Meta-analysis of observational studies in epidemiology: a proposal for reporting,” JAMA, vol. 283, no. 15, pp. 2008–2012, 2000.

[37] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” PLoS Medicine, vol. 6, no. 7, article e1000097, 2009.

[38] E. Stovold, D. Beecher, R. Foxlee, and A. Noel-Storr, “Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram,” Systematic Reviews, vol. 3, no. 1, p. 54, 2014.

[39] J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011], The Cochrane Collaboration, 2011.

[40] A. Wells, B. Shea, D. O’Connell et al., “The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses,” http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

[41] I. R. White and J. Thomas, “Standardized mean differences in individually-randomized and cluster-randomized trials, with applications to meta-analysis,” Clinical Trials: Journal of the Society for Clinical Trials, vol. 2, no. 2, pp. 141–151, 2005.

[42] M. Borenstein, L. V. Hedges, J. P. T. Higgins, and H. R. Rothstein, “Fixed-effect versus random-effects models,” in Introduction to Meta-Analysis, pp. 77–86, John Wiley & Sons, Ltd., 2009.

[43] M. Borenstein, J. P. T. Higgins, L. V. Hedges, and H. R. Rothstein, “Basics of meta-analysis: F is not an absolute measure of heterogeneity,” Research Synthesis Methods, vol. 8, no. 1, pp. 5–18, 2017.

[44] B. Baujat, C. Mahe, J. P. Pignon, and C. Hill, “A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials,” Statistics in Medicine, vol. 21, no. 18, pp. 2641–2652, 2002.

[45] J. Lau, C. H. Schmid, and T. C. Chalmers, “Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care,” Journal of Clinical Epidemiology, vol. 48, no. 1, pp. 45–57, 1995.

[46] M. Borenstein, L. V. Hedges, J. P. T. Higgins, and H. R. Rothstein, Introduction to Meta-Analysis, John Wiley & Sons, Ltd., 2009.

[47] G. Schwarzer, “Meta: an R package for meta-analysis,” R News, vol. 7, no. 3, pp. 40–45, 2007.

[48] Y. Winhoro, A. Handisurya, A. Tura et al., “Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus,” Diabetes Care, vol. 33, no. 1, pp. 139–143, 2010.

[49] N. Tabatabaei, Y. Giguerre, J. C. Forest, C. J. Rodd, R. Kremer, and H. A. Weiler, “Osteocalcin is higher across pregnancy in
Caucasian women with gestational diabetes mellitus,” *Canadian Journal of Diabetes*, vol. 38, no. 5, pp. 307–313, 2014.

[50] P. Srichomkwun, N. Houngngam, S. Pasatrat, T. Tharavanij, L. Wattanachanya, and W. Khovidhunkit, “Undercarboxylated osteocalcin is associated with insulin resistance, but not adiponectin, during pregnancy,” *Endocrine*, vol. 53, no. 1, pp. 129–135, 2016.

[51] Y. Winhofer, F. W. Kiefer, A. Handisurya et al., “CTX (crosslaps) rather than osteopontin is associated with disturbed glucose metabolism in gestational diabetes,” *PLoS One*, vol. 7, no. 7, article e40947, 2012.

[52] B. Telejko, K. Kalejta, M. Kuzmicki et al., “The association of bone turnover markers with pro- and anti-inflammatory adipokines in patients with gestational diabetes,” *Annals of Agricultural and Environmental Medicine*, vol. 22, no. 2, pp. 307–312, 2015.

[53] M. Martinez, P. Catalan, A. Lisbona et al., “Serum osteocalcin concentrations in diabetic pregnant women and their newborns,” *Hormone and Metabolic Research*, vol. 26, no. 7, pp. 338–342, 1994.

[54] M. B. Landon, C. Y. Spong, E. Thom et al., “A multicenter, randomized trial of treatment for mild gestational diabetes,” *The New England Journal of Medicine*, vol. 361, no. 14, pp. 1339–1348, 2009.

[55] C. A. Crowther, J. E. Hiller, J. R. Moss et al., “Effect of treatment of gestational diabetes mellitus on pregnancy outcomes,” *The New England Journal of Medicine*, vol. 352, no. 24, pp. 2477–2486, 2005.

[56] N. Oostdam, M. N. M. van Poppel, M. G. A. J. Wouters, and W. van Mechelen, “Interventions for preventing gestational diabetes mellitus: a systematic review and meta-analysis,” *Journal of Women’s Health*, vol. 20, no. 10, pp. 1551–1563, 2011.

[57] S. Thangaratinam, E. Rogozinska, K. Jolly et al., “Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence,” *BMJ*, vol. 344, no. may16 4, p. e2088, 2012.

[58] E. Caliskan, F. Kayikcioglu, N. Ozturk, S. Koc, and A. Haberal, “A population-based risk factor scoring will decrease unnecessary testing for the diagnosis of gestational diabetes mellitus,” *Acta Obstetricia et Gynecologica Scandinavica*, vol. 83, no. 6, pp. 524–530, 2004.

[59] S. Nanda, M. Savvidou, A. Syngelaki, R. Akolekar, and K. H. Nicolaides, "Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks," *Prenatal Diagnosis*, vol. 31, no. 2, pp. 135–141, 2011.

[60] C. D. Naylor, M. Sermer, E. Chen, and D. Farine, “Selective screening for gestational diabetes mellitus,” *The New England Journal of Medicine*, vol. 337, no. 22, pp. 1591–1596, 1997.

[61] H. J. Teede, C. L. Harrison, W. T. Teh, E. Paul, and C. A. Allan, “Gestational diabetes: development of an early risk prediction tool to facilitate opportunities for prevention,” *Australian and New Zealand Journal of Obstetrics and Gynaecology*, vol. 51, no. 6, pp. 499–504, 2011.

[62] M. van Leeuwen, B. C. Opmeer, E. J. K. Zweers et al., “Estimating the risk of gestational diabetes mellitus: a clinical prediction model based on patient characteristics and medical history,” *BJOG: An International Journal of Obstetrics & Gynaecology*, vol. 117, no. 1, pp. 69–75, 2010.

[63] G. Karsenty and F. Oury, “Regulation of male fertility by the bone-derived hormone osteocalcin,” *Molecular and Cellular Endocrinology*, vol. 382, no. 1, pp. 521–526, 2014.

[64] J. Wei, T. Hanna, N. Suda, G. Karsenty, and P. Ducy, “Osteocalcin promotes β-cell proliferation during development and adulthood through Gprc6a,” *Diabetes*, vol. 63, no. 3, pp. 1021–1031, 2014.

[65] M. Pi, Y. Wu, and L. D. Quarles, “GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo,” *Journal of Bone and Mineral Research*, vol. 26, no. 7, pp. 1680–1683, 2011.